“First, with our Transradial Catheter, which is on track to launch in the second half of fiscal year '27”

In context

“nsion. We're seeing strong patient outcomes in the field and the already in value proposition, it resonates with both physicians and patients. Now we've got strong and growing clinical data, a broad label and expanding reimbursement all in hand Look, we've built the foundation. Now we're focused on growing this new segment and transforming the hypertension treatment paradigm. We've recently activated our direct-to-consumer Go Beyond campaign in key markets around the U.S., which is resulting in a 50x increase in website visits versus the prior quarter. So a lot of interest coming in from patients. Building a new market, it does take time, but that is something Medtronic knows how to do exceptionally well. And in parallel to building out this new market, we're innovating for the long term. First, with our Transradial Catheter, which is on track to launch in the second half of fiscal year '27 and with our Spiral Gemini trial evaluating multi-organ ablation to further boost efficacy. Now similarly, we are scaling Altaviva, our tibial neurostimulation device. Altaviva is a simple yet transformational option for treating urge urinary incontinence, which is a condition that affects 1 million people in the U.S. Altaviva is a very small device that requires no imaging, no sedation, activates the same day, is MRI ready and offers up to 15 years of battery life, the longest in its category. Again, we are receiving great early interest and feedback from both physicians and patients. And we are training doctors. We're educating and supporting hospital staff and investing in omnichannel consumer activation. Look, it's early days for both of these launches, and we are focused on disciplin”